Gautam Megha, Gabrani Reema
Department of Biotechnology, Jaypee Institute of Information Technology, Noida, 201309, India.
Curr Med Sci. 2024 Dec;44(6):1175-1184. doi: 10.1007/s11596-024-2950-7. Epub 2024 Dec 19.
There are several types of brain tumors but glioblastoma (GBM) is one of the highly malignant tumors. A primary concern with GBM is that the treatment is inadequate. Even after giving many multi-stacked combinations of therapies to patients, inclusive of chemotherapy, radiation, and surgery, the median survival rate remains poor. Due to its heterogeneous nature, the use of selective therapy for specific targeting of tumor cells is of particular importance. Although many treatment alternatives which include surgery with adjuvant chemotherapy and radiotherapy are available, the prognosis of the disease is very poor. Combination therapy is becoming the foundation of modern antitumor therapy and it is continuously evolving and developing innovative drug regimens as evidenced by ongoing preclinical and clinical trials. In this review, we discuss the current treatment options and emerging therapeutic approaches for the treatment of GBM. The prospects for alternative glioblastoma therapy are also discussed.
脑肿瘤有多种类型，但胶质母细胞瘤（GBM）是高度恶性肿瘤之一。GBM的一个主要问题是治疗不充分。即使给患者使用了多种联合治疗方案，包括化疗、放疗和手术，其中位生存率仍然很低。由于其异质性，使用选择性疗法特异性靶向肿瘤细胞尤为重要。尽管有许多治疗选择，包括手术联合辅助化疗和放疗，但该疾病的预后非常差。联合治疗正成为现代抗肿瘤治疗的基础，并且正如正在进行的临床前和临床试验所证明的那样，它在不断发展并开发创新的药物方案。在这篇综述中，我们讨论了目前治疗GBM的选择和新兴的治疗方法。还讨论了胶质母细胞瘤替代疗法的前景。
